- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01395849
Drug Use Investigation for ADOAIR (Fluticasone/Salmeterol)
May 15, 2017 updated by: GlaxoSmithKline
The purpose of this post-marketing surveillance is to detect adverse drug reactions (particularly clinically significant adverse drug reactions) occurring in clinical settings, to examine factors likely to affect the safety and efficacy in the Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
2116
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Japanese patients with asthma
Description
Inclusion Criteria:
- Must use fluticasone and salmeterol for the first time
Exclusion Criteria:
- Patients with hypersensitivity to salmeterol and fluticasone
- Patients with infection which salmeterol and fluticasone is not effective
- Patients with deep mycosis
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients prescribed fluticasone and salmeterol
Patients with asthma prescribed fluticasone and salmeterol during study period
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The number of incidence of adverse events in Japanese asthma patients treated with fluticasone propionate and salmeterol xinafoate
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2007
Primary Completion (Actual)
September 1, 2009
Study Completion (Actual)
March 1, 2011
Study Registration Dates
First Submitted
July 14, 2011
First Submitted That Met QC Criteria
July 14, 2011
First Posted (Estimate)
July 18, 2011
Study Record Updates
Last Update Posted (Actual)
May 16, 2017
Last Update Submitted That Met QC Criteria
May 15, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiration Disorders
- Respiratory Tract Diseases
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Adrenergic Agonists
- Dermatologic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Sympathomimetics
- Fluticasone
- Salmeterol Xinafoate
- Fluticasone-Salmeterol Drug Combination
Other Study ID Numbers
- 112277
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Respiratory Disorders
-
LmecaRecruitingOther Specified Respiratory DisordersKorea, Republic of
-
Centro Universitário Augusto MottaUniversidade Federal do Rio de JaneiroCompletedRespiratory Failure | Respiratory DisordersBrazil
-
Mustafa Kemal UniversityThe Scientific and Technological Research Council of TurkeyCompletedMood Disorders | Physical Inactivity | Respiratory Function ImpairedTurkey
-
Children's Hospital Medical Center, CincinnatiRecruitingRespiratory DisordersUnited States
-
Children's Hospital Medical Center, CincinnatiRecruitingRespiratory DisordersUnited States
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedRespiratory Disorders
-
Hollister IncorporatedTerminatedRespiratory Failure | Ventilatory Depression | Respiratory DepressionUnited States
-
RespireRxDuke UniversityUnknownOpiate Induced Respiratory DepressionUnited States
-
Leiden University Medical CenterNot yet recruitingDepressive Disorder | Anxiety Disorders | Opioid Induced Respiratory Depression
Clinical Trials on Salmeterol and Fluticasone
-
Arthur F Gelb MDCompleted
-
Neovii BiotechFresenius Biotech North AmericaCompletedOvarian CancerUnited States
-
University of DundeeCompleted
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary DiseaseChina, Argentina, Taiwan, Chile
-
Respirent Pharmaceuticals Co Ltd.Becro Ltd.Completed
-
GlaxoSmithKlineWithdrawnPulmonary Disease, Chronic Obstructive
-
Johns Hopkins UniversityGlaxoSmithKline; American Lung AssociationCompleted
-
GlaxoSmithKlineCompleted
-
University of MiamiGlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedAsthmaUnited States, Argentina, Philippines, Canada, Brazil